NPPA Retail Price Fixation for Pharmaceutical Formulations
The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has issued an order dated November 28, 2025 fixing the retail price (exclusive of Goods and Services Tax, GST) for several drug formulations.
NPPA Extends Ceiling Prices for Knee Implants Until November 2026
The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has extended the existing ceiling prices for Orthopaedic Knee Implants for Knee Replacement System for a period of one year.
NPPA Adds Manufacturers to Ceiling Price Order for IV Fluids
The National Pharmaceutical Pricing Authority (NPPA) has issued an addendum, dated November 4, 2025, to its previous orders (No. 1486(E) dated March 27, 2025, and No. 3976(E) dated August 29, 2025) concerning the ceiling price fixation of scheduled intravenous (I.V.) fluid packs (specifically non-Glass with special features).
NPPA Fixes Retail Prices for 28 Formulations, Including Diabetes and Hypertension Drugs
The National Pharmaceutical Pricing Authority (NPPA) has issued an order to fix the retail prices for 28 specific drug formulations under the powers conferred by the Drugs (Prices Control) Order, 2013 (DPCO, 2013). This order, dated November 4, 2025, sets the maximum retail price, exclusive of Goods and Services Tax (GST), for each formulation manufactured by the specified companies.
NPPA Extends Price Caps on Knee Implants Amidst Industry Review
The National Pharmaceutical Pricing Authority (NPPA), India’s primary drug and medical device pricing regulator, has announced a crucial two-month extension of the price caps on orthopaedic knee implants. The decision, formalized in a notification on September 15, 2025, extends the existing price control measures from their expiry date of September 15, 2025, to November 15, 2025. This move comes as the authority deliberates on various representations it has received from manufacturers and industry associations, signaling a period of intense review that could reshape the future of medical device pricing in the country.
NPPA Fixes Retail Prices for Nine New Drugs
The National Pharmaceutical Pricing Authority (NPPA), in a decisive move to regulate the cost of essential medicines, has officially fixed the retail prices for nine new drug formulations. This order, issued on September 15, 2025, sets the maximum prices for a range of new medicines, including advanced combination therapies for pain management, diabetes, and cardiovascular conditions. The action is in line with the objectives of the Drugs (Prices Control) Order, 2013 (DPCO, 2013).